[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DZ3150A1 - Nouveau procédé de traitement. - Google Patents

Nouveau procédé de traitement.

Info

Publication number
DZ3150A1
DZ3150A1 DZ003150A DZ003150A DZ3150A1 DZ 3150 A1 DZ3150 A1 DZ 3150A1 DZ 003150 A DZ003150 A DZ 003150A DZ 003150 A DZ003150 A DZ 003150A DZ 3150 A1 DZ3150 A1 DZ 3150A1
Authority
DZ
Algeria
Prior art keywords
treatment process
new treatment
new
treatment
Prior art date
Application number
DZ003150A
Other languages
English (en)
French (fr)
Inventor
Creighton P Conley
John A Roush
Kevin H Storm
Original Assignee
Beecham Pharm Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27383840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ3150(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Pharm Pte Ltd filed Critical Beecham Pharm Pte Ltd
Application granted granted Critical
Publication of DZ3150A1 publication Critical patent/DZ3150A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
DZ003150A 1999-04-13 2000-04-11 Nouveau procédé de traitement. DZ3150A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12907499P 1999-04-13 1999-04-13
US15072799P 1999-08-25 1999-08-25
US15981399P 1999-10-15 1999-10-15
PCT/IB2000/000992 WO2000061116A2 (en) 1999-04-13 2000-04-11 Pharmaceutical formulation comprising amoxycillin and clavulanate

Publications (1)

Publication Number Publication Date
DZ3150A1 true DZ3150A1 (fr) 2000-10-19

Family

ID=27383840

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003150A DZ3150A1 (fr) 1999-04-13 2000-04-11 Nouveau procédé de traitement.

Country Status (45)

Country Link
EP (4) EP1044680B1 (ja)
JP (2) JP4880125B2 (ja)
KR (1) KR100634937B1 (ja)
CN (1) CN100382782C (ja)
AP (1) AP1806A (ja)
AR (1) AR031068A1 (ja)
AT (2) AT4327U1 (ja)
AU (1) AU767177B2 (ja)
BE (2) BE1013309A5 (ja)
BG (1) BG65006B1 (ja)
BR (1) BRPI0009719B8 (ja)
CA (1) CA2366304C (ja)
CO (1) CO5170471A1 (ja)
CZ (1) CZ298801B6 (ja)
DE (3) DE60003255T2 (ja)
DK (3) DK200000602A (ja)
DZ (1) DZ3150A1 (ja)
EA (1) EA004310B1 (ja)
ES (2) ES2202004T3 (ja)
FI (2) FI20000863A (ja)
FR (1) FR2792198A1 (ja)
GB (1) GB2351661B (ja)
GR (1) GR1003560B (ja)
HK (1) HK1032741A1 (ja)
HU (1) HU229097B1 (ja)
IE (1) IE20000271A1 (ja)
IL (2) IL145580A0 (ja)
IT (1) ITMI20000788A1 (ja)
MA (1) MA25352A1 (ja)
MX (1) MXPA01010377A (ja)
MY (1) MY119953A (ja)
NL (2) NL1014915C2 (ja)
NO (1) NO329694B1 (ja)
NZ (1) NZ514575A (ja)
OA (1) OA11926A (ja)
PE (1) PE20010053A1 (ja)
PL (1) PL197448B1 (ja)
PT (2) PT1044680E (ja)
RO (1) RO120817B1 (ja)
SE (1) SE0001330L (ja)
SI (2) SI1044680T1 (ja)
SK (1) SK285140B6 (ja)
TR (1) TR200102963T2 (ja)
TW (1) TWI235067B (ja)
WO (1) WO2000061116A2 (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
AU711441B2 (en) 1995-09-07 1999-10-14 Smithkline Beecham Plc Pharmaceutical formulation
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
AU2001292185A1 (en) * 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
AU2002320309B2 (en) 2001-07-06 2007-07-12 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
WO2003086267A2 (en) * 2002-04-10 2003-10-23 Miller Fred H Multi-phase, multi-compartment capsular system
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
EP1541129A1 (en) * 2003-12-12 2005-06-15 Cimex AG Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005099672A1 (en) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EP1880716A1 (en) * 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
EP2079453A1 (en) * 2006-10-10 2009-07-22 Penwest Pharmaceuticals Co. Robust sustained release formulations
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
CA2981759C (en) * 2015-04-07 2021-10-12 Church & Dwight Co., Inc. Multicomponent gummy compositions with soft core
CN109394718B (zh) * 2018-11-15 2021-04-27 石药集团中诺药业（石家庄）有限公司 一种阿莫西林分散片及其制备方法
CN110051637A (zh) * 2019-05-21 2019-07-26 葵花药业集团北京药物研究院有限公司 阿莫西林克拉维酸钾制剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2964817D1 (en) * 1978-09-06 1983-03-24 Beecham Group Plc Pharmaceutical compositions containing two beta-lactam derivatives
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
DE69425131T2 (de) * 1993-01-22 2001-03-15 Smithkline Beecham P.L.C., Brentford Verwendung von clavulansäure und einem antibiotikum zur behandlung von infektionen
GB9311030D0 (en) * 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) * 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
AU711441B2 (en) * 1995-09-07 1999-10-14 Smithkline Beecham Plc Pharmaceutical formulation
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
ATE243516T1 (de) * 1997-02-14 2003-07-15 Glaxosmithkline Lab Sas Amoxicillin und clavulanat enthaltende arzneizubereitungen
SK121099A3 (en) * 1997-03-11 2000-06-12 Almag Al Process and apparatus for coating metals
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
EP0973498B1 (en) * 1997-03-25 2005-01-12 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent pharmaceutical composition
JP3746901B2 (ja) * 1997-10-15 2006-02-22 ユニ・チャーム株式会社 開閉自在容器
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
US6225304B1 (en) * 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Also Published As

Publication number Publication date
PL197448B1 (pl) 2008-03-31
SK285140B6 (sk) 2006-07-07
NO20001870D0 (no) 2000-04-11
EP1044680B1 (en) 2003-06-11
EP1270005A3 (en) 2006-05-17
SI1044680T1 (en) 2003-12-31
DE60003255D1 (de) 2003-07-17
JP4880125B2 (ja) 2012-02-22
HU0001471D0 (en) 2000-06-28
HUP0001471A2 (en) 2001-03-28
WO2000061116A3 (en) 2001-02-01
DE10017883A1 (de) 2000-10-26
EP1269997A1 (en) 2003-01-02
WO2000061116A2 (en) 2000-10-19
PL339591A1 (en) 2000-10-23
CZ20001311A3 (cs) 2000-11-15
AP2001002284A0 (en) 2001-12-31
GB0008923D0 (en) 2000-05-31
NL1014915C2 (nl) 2001-02-12
MXPA01010377A (es) 2002-10-23
BE1013309A5 (fr) 2001-11-06
BE1012733A6 (fr) 2001-02-06
EP1270005A2 (en) 2003-01-02
EP1269996A1 (en) 2003-01-02
HK1032741A1 (en) 2001-08-03
PT102450B (pt) 2003-09-30
NZ514575A (en) 2004-05-28
PT1044680E (pt) 2003-10-31
BG65006B1 (bg) 2006-12-29
EP1044680A1 (en) 2000-10-18
FR2792198A1 (fr) 2000-10-20
BR0009719A (pt) 2002-01-08
IL145580A (en) 2007-05-15
CN100382782C (zh) 2008-04-23
SI20304A (sl) 2001-02-28
GB2351661B (en) 2001-10-10
SE0001330L (sv) 2000-10-14
AU767177B2 (en) 2003-11-06
FIU20000164U0 (fi) 2000-04-11
DK200000133U3 (da) 2000-07-28
ES2190692A1 (es) 2003-08-01
NL1014915A1 (nl) 2000-10-16
AP1806A (en) 2007-12-14
FI20000863A0 (fi) 2000-04-11
MA25352A1 (fr) 2001-12-31
PT102450A (pt) 2001-02-01
ITMI20000788A0 (it) 2000-04-11
AT4327U1 (de) 2001-06-25
CO5170471A1 (es) 2002-06-27
BR0009719B1 (pt) 2014-09-30
FI4823U1 (fi) 2001-02-16
ITMI20000788A1 (it) 2001-10-11
NO329694B1 (no) 2010-12-06
NL1014914C1 (nl) 2000-10-16
JP2002541187A (ja) 2002-12-03
DK200000602A (da) 2000-10-14
CA2366304C (en) 2004-06-29
KR20020015312A (ko) 2002-02-27
TWI235067B (en) 2005-07-01
AU5702000A (en) 2000-11-14
MY119953A (en) 2005-08-30
OA11926A (en) 2006-04-12
KR100634937B1 (ko) 2006-10-17
GR1003560B (el) 2001-03-16
DE60003255T2 (de) 2004-05-06
EA004310B1 (ru) 2004-02-26
GB2351661A (en) 2001-01-10
CZ298801B6 (cs) 2008-02-06
AR031068A1 (es) 2003-09-10
EA200101075A1 (ru) 2002-04-25
ATE242629T1 (de) 2003-06-15
IE20000271A1 (en) 2001-04-04
FI20000863A (fi) 2000-10-13
SE0001330D0 (sv) 2000-04-11
BRPI0009719B8 (pt) 2021-05-25
DK1044680T3 (da) 2003-09-29
CN1382040A (zh) 2002-11-27
BG104329A (en) 2001-11-30
CA2366304A1 (en) 2000-10-19
IL145580A0 (en) 2002-11-10
DE20006626U1 (de) 2000-10-19
TR200102963T2 (tr) 2002-02-21
RO120817B1 (ro) 2006-08-30
JP2011256180A (ja) 2011-12-22
NO20001870L (no) 2000-10-16
HUP0001471A3 (en) 2001-10-29
ES2202004T3 (es) 2004-04-01
HU229097B1 (en) 2013-07-29
PE20010053A1 (es) 2001-03-10
SK5342000A3 (en) 2000-11-07
ES2190692B1 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
DZ3150A1 (fr) Nouveau procédé de traitement.
DZ3151A1 (fr) Nouveau procédé de traitement.
AR024800A1 (es) Proceso de produccion de fenil-alcanos
FR2814945B1 (fr) Procede de traitement de la canitie
DE60030210D1 (de) Elektrolytisches Behandlungsverfahren
DE69828821D1 (de) Wasserbehandlungsverfahren
NO20015613D0 (no) Fremgangsmåte for polymerisasjon
NO20022851D0 (no) Fremgangsmåte for polymerisasjon
DE60007050D1 (de) IMC-Verfahren
FR2797262B1 (fr) Procede de traitement de materiau architectural
DE60042953D1 (de) Oxidationsverfahren
ATE269391T1 (de) Wäschebehandlung
HUP0201121A3 (en) Underwear rinsing materials, process for producing said materials an process for treating underwear
FI991220A0 (fi) Menetelmä massan käsittelemiseksi
FR2788234B1 (fr) Procede de chanfreinage
NO20006540D0 (no) Fremgangsmåte for dampkoking av reker
HK1032561A1 (en) Process for treatment of contact lens.
MA25522A1 (fr) Procede de traitement de copd
NO20013596L (no) Slambehandling
ATE290060T1 (de) Wäschebehandlung
FI990127A0 (fi) Menetelmä massan käsittelemiseksi
DE69929561D1 (de) Laufrolle, Herstellungsverfahren
NO20006383L (no) Fremgangsmåte for behandling
FR2800096B1 (fr) Procede de traitement des scories
FR2817776B1 (fr) Procede de traitement de farines contaminees